Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study proposes a new direction to investigate the molecular mechanisms underlying the invasion and metastasis of CRC, whereby the interaction between MALAT1 and miR-20b-5p could be a novel therapeutic target for CRC.
|
30716387 |
2019 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In vitro and in vivo invasion and metastasis assays were used to explore the function of MALAT1/miR-106b-5p/SLAIN2 in the progression of CRC.
|
30797712 |
2019 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study first revealed the novel roles of MALAT1 in promoting CRC metastasis through two mechanisms: first, MALAT1 binds miR-15 family members, to "de-inhibit" their effect on LRP6 expression, enhances β-catenin signaling, leading to elevated transcriptional levels of downstream target genes RUNX2.
|
31097689 |
2019 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multivariate Cox regression analysis showed that MALAT1 was a poor prognostic factor of colorectal cancer.
|
31311811 |
2019 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The long non-coding RNA MALAT1 promotes epithelial-mesenchymal transition and angiogenesis in colorectal cancer, but it is unknown whether it affects the stemness of gastric cancer cells.
|
31037832 |
2019 |
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Collectively, we concluded that MALAT1 functioned as a ceRNA to promote colorectal cancer development and EZH2 expression through sponging miR-363-3p <i>in vitro</i> and <i>in vivo</i>.
|
30972996 |
2019 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings indicated that the YAP1-MALAT1-miR-126-5p axis could control angiogenesis and epithelial-mesenchymal transition in CRC, providing potential biomarkers and therapeutic targets for CRC.
|
30531836 |
2019 |
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data demonstrated that JMJD2C could enhance the metastatic abilities of CRC cells in vitro and in vivo by regulating the histone methylation level of MALAT1 promoter, thereby up-regulating the expression of MALAT1 and enhancing the activity of β-catenin signaling pathway, providing that JMJD2C might be a novel therapeutic target for CRC metastasis.
|
31665047 |
2019 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nonetheless, whether Malat1 participates in the autophagy of colorectal cancer remains unclear.
|
31372165 |
2019 |
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In particular, increased MALAT1 expression levels were significantly associated with decreased OS in patients with colorectal cancer (HR, 3.04; 95% CI, 1.77-4.31).
|
30719108 |
2019 |
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally, we investigated the clinical role of MALAT1 and found that high lncRNA MALAT1 expression level is associated with poor prognosis in CRC patients receiving oxymatrine treatment (P<0.01).
|
29328404 |
2018 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the molecular mechanisms by which MALAT1 and DCP1A may be linked to contribute to the malignancies of CRCs.
|
29964337 |
2018 |
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Taken together, our findings provided strong evidence for the hypothesis that genetic variants in lncRNA MALAT1 might contribute to the carcinogenesis of CRC.
|
30538572 |
2018 |
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MALAT1 can be aberrantly expressed in hepatocellular carcinoma, cervical, breast, ovarian cancers, as well as colorectal cancer.
|
29096355 |
2018 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
LncRNA MALAT1 could facilitate colorectal cancer cell proliferation, invasion and migration by down-regulating miR-145 and up-regulating SOX9.
|
30285605 |
2018 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
EZH2 is highly expressed and associated with the 3' end region of lncRNA MALAT1 in colorectal cancer, and this association suppressed the expression of E-cadherin.
|
28069878 |
2017 |
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we investigated the molecular mechanism by which MALAT1 enhances AKAP9 expression in CRC SW480 cells.
|
26887056 |
2016 |
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
An aberrant expression of MALAT1 was observed in hepatocellular carcinoma, cervical cancer, breast cancer, ovarian cancer, and colorectal cancer.
|
25431257 |
2015 |
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Recent studies have demonstrated that MALAT1 is involved in cancer metastasis and recurrence and it is up-regulated in cervical cancer, hepatocellular carcinoma, non-small cell lung cancer (NSCLC) and colorectal cancer.
|
26406400 |
2015 |
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Multivariate analyses indicated that MALAT1 expression and perineural invasion were two independent prognostic risk factors for patients with CRC.
|
25031737 |
2014 |
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Using MALAT1 lentiviral shRNA and over-expression constructs in CRC derived cell lines, LoVo and HCT116, we demonstrated that the anti-tumor effects of resveratrol on CRC are through inhibiting Wnt/β-catenin signaling, thus the expression of its target genes such as c-Myc, MMP-7, as well as the expression of MALAT1.
|
24244343 |
2013 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have successfully presented the first evidence that mutations were found on the long non-coding RNA MALAT-1 in CRC.
|
21503572 |
2011 |